Provenge Sales Disappoint, but Dendreon Shows Growth

Dendreon Corp. reported its third-quarter earnings, handing in a net loss of $154.9 million, or $1.04 per share. That loss was larger than consensus estimates. Provenge (sipuleucel-T) revenues also fell short of consensus, at $78 million, vs. $80.7 million.